Cargando…
Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms
Buprenorphine is a partial mu agonist and kappa antagonist which is used for the treatment of pain and opioid addiction. A mixture of buprenorphine hydrochloride and naloxone hydrochloride has been approved for the treatment of opioid dependence. In this study a third order derivative spectrophotome...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423238/ https://www.ncbi.nlm.nih.gov/pubmed/28496466 |
_version_ | 1783234904208703488 |
---|---|
author | Souri, Effat Ahmadi, Farzaneh Sadat Barazandeh Tehrani, Maliheh Hosseini, Majid Mohammad Fadaye Vatan, Sedigheh |
author_facet | Souri, Effat Ahmadi, Farzaneh Sadat Barazandeh Tehrani, Maliheh Hosseini, Majid Mohammad Fadaye Vatan, Sedigheh |
author_sort | Souri, Effat |
collection | PubMed |
description | Buprenorphine is a partial mu agonist and kappa antagonist which is used for the treatment of pain and opioid addiction. A mixture of buprenorphine hydrochloride and naloxone hydrochloride has been approved for the treatment of opioid dependence. In this study a third order derivative spectrophotometric method based on zero-crossing technique has been used for the simultaneous determination of buprenorphine hydrochloride and naloxone hydrochloride in tablets. The measurements were carried out at wavelengths of 257.8 (zero-crossing point of naloxone hydrochloride) and 252.2 nm (zero-crossing point of buprenorphice hydrochloride) for buprenorphine hydrochloride and naloxone hydrochloride, respectively in the third order derivative spectra obtained in methanol and 0.1 M NaOH (50:50) as solvent. The method was found to be linear in the range of 20-80 µg/mL for buprenorphine hydrochloride and 5-20 µg/mL for naloxone hydrochloride. The within-day and between-day coefficient of variation and error values were less than 2.5% and 1.8%, respectively. The proposed method was successfully used for simultaneous determination of these drugs in pharmaceutical dosage form without any interference from excipients or need to prior separation before analysis. |
format | Online Article Text |
id | pubmed-5423238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Shaheed Beheshti University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-54232382017-05-11 Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms Souri, Effat Ahmadi, Farzaneh Sadat Barazandeh Tehrani, Maliheh Hosseini, Majid Mohammad Fadaye Vatan, Sedigheh Iran J Pharm Res Original Article Buprenorphine is a partial mu agonist and kappa antagonist which is used for the treatment of pain and opioid addiction. A mixture of buprenorphine hydrochloride and naloxone hydrochloride has been approved for the treatment of opioid dependence. In this study a third order derivative spectrophotometric method based on zero-crossing technique has been used for the simultaneous determination of buprenorphine hydrochloride and naloxone hydrochloride in tablets. The measurements were carried out at wavelengths of 257.8 (zero-crossing point of naloxone hydrochloride) and 252.2 nm (zero-crossing point of buprenorphice hydrochloride) for buprenorphine hydrochloride and naloxone hydrochloride, respectively in the third order derivative spectra obtained in methanol and 0.1 M NaOH (50:50) as solvent. The method was found to be linear in the range of 20-80 µg/mL for buprenorphine hydrochloride and 5-20 µg/mL for naloxone hydrochloride. The within-day and between-day coefficient of variation and error values were less than 2.5% and 1.8%, respectively. The proposed method was successfully used for simultaneous determination of these drugs in pharmaceutical dosage form without any interference from excipients or need to prior separation before analysis. Shaheed Beheshti University of Medical Sciences 2017 /pmc/articles/PMC5423238/ /pubmed/28496466 Text en ©2017 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Souri, Effat Ahmadi, Farzaneh Sadat Barazandeh Tehrani, Maliheh Hosseini, Majid Mohammad Fadaye Vatan, Sedigheh Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms |
title | Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms |
title_full | Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms |
title_fullStr | Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms |
title_full_unstemmed | Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms |
title_short | Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms |
title_sort | validated spectrophtometric method for simultaneous determination of buprenorphine and naloxone in pharmaceutical dosage forms |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423238/ https://www.ncbi.nlm.nih.gov/pubmed/28496466 |
work_keys_str_mv | AT sourieffat validatedspectrophtometricmethodforsimultaneousdeterminationofbuprenorphineandnaloxoneinpharmaceuticaldosageforms AT ahmadifarzanehsadat validatedspectrophtometricmethodforsimultaneousdeterminationofbuprenorphineandnaloxoneinpharmaceuticaldosageforms AT barazandehtehranimaliheh validatedspectrophtometricmethodforsimultaneousdeterminationofbuprenorphineandnaloxoneinpharmaceuticaldosageforms AT hosseinimajidmohammad validatedspectrophtometricmethodforsimultaneousdeterminationofbuprenorphineandnaloxoneinpharmaceuticaldosageforms AT fadayevatansedigheh validatedspectrophtometricmethodforsimultaneousdeterminationofbuprenorphineandnaloxoneinpharmaceuticaldosageforms |